Levetiracetam Stragen (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, decreasing abnormal neuronal firing and reducing overall neuronal excitability, thereby helping to control seizure activity.

The appropriate dose of Levetiracetam Stragen is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and overall clinical condition. No fixed dosing regimen is provided here; the prescriber tailors therapy to each individual.

The pregnancy category for Levetiracetam Stragen is listed as unknown. Use during pregnancy or lactation should only occur when the potential therapeutic benefit justifies any possible risk to the fetus or infant, and it must be decided by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levetiracetam Stragen. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Compared with older agents such as carbamazepine or valproic acid, levetiracetam has a distinct mechanism (SV2A binding) and a generally favorable drug‑interaction profile. It does not require routine therapeutic drug monitoring, but clinicians still consider individual patient factors, tolerability, and potential interactions when selecting therapy.

Levetiracetam Stragen should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, consult the supplier before use.

The product is supplied as an injectable solution for intravenous use. It is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional, typically as a slow infusion over a prescribed period to achieve the desired plasma concentration.

Serious adverse events include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or other severe skin eruptions, and the emergence of suicidal thoughts or behavior. Patients should be monitored closely for any signs of these reactions, and immediate medical attention is required if they occur.

Levetiracetam Stragen is contraindicated in individuals with known hypersensitivity to levetiracetam or any component of the formulation. Patients with severe renal impairment should not receive the product without appropriate dose adjustment, and it should be used with caution in those with a history of psychiatric disorders.